Profile
| Metric | Value |
|---|---|
| Full Name | Biogen Inc. |
| Ticker | NASDAQ: BIIB |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | biogen.com |
| Employees | 7,605 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $182.61 | |
| Price, 1D Change | +4.57% | |
| Market Cap | $27B | |
| - | ||
| PE Ratio | 16.65 | |
| Beta | 0.57 | |
| Revenue | $9B | |
| Revenue, 1Y Change | -1.60% | |
| EPS | $11.19 | |
| EPS, 1Y Change | +40.28% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 3:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | IDPH | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $11.19 | |
| EPS Estimate | $15.03 | |
| EPS Est. Change | +34.35% | |
| Revenue | $9.27B | |
| Revenue Estimate | $9.82B | |
| Revenue Est. Change | +6.00% | |
| Current Price | $182.61 | |
| Price Target | - | $181.00 |
| Price Tgt. Change | - | -0.88% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $14.99 | $7.97 | -46.80% | |
| $16.37 | $11.19 | -31.68% | |
| $15.03 | N/A | +34.35% | |
| $15.16 | N/A | +35.56% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.93B | $9.42B | -5.15% | |
| $9.64B | $9.27B | -3.87% | |
| $9.82B | N/A | +6.00% | |
| $9.29B | N/A | +0.30% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +19.14% | |
| Price, 3Y | -34.61% | |
| Market Cap, 1Y | +19.95% | |
| Market Cap, 3Y | -33.38% | |
| Revenue, 1Y | -1.60% | |
| Revenue, 3Y | -10.92% | |
| EPS, 1Y | +40.28% | |
| EPS, 3Y | +7.55% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $182.61 | |
| SMA 200 | $141.73 | |
| SMA 200 vs Price | -22.38% | |
| SMA 50 | $169.17 | |
| SMA 50 vs Price | -7.36% | |
| Beta | 0.57 | |
| ATR | $4.78 | |
| 14-Day RSI | 63.98 | |
| 10-Day Volatility | 26.03% | |
| 1-Year Volatility | 32.68% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $9.27B | |
| EPS | $11.19 | |
| Gross Profit | $7.37B | |
| Gross Margin | 76.12% | |
| Operating Profit | $2.22B | |
| Operating Margin | 22.93% | |
| Net Income | $1.63B | |
| Net Margin | 16.87% | |
| EBITDA | $2.83B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.38 | |
| Current Ratio | 1.35 | |
| Quick Ratio | 0.90 | |
| - | ||
| F-Score | 5 | |
| Altman Z-Score | 3.05 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 16.65 | |
| PS Ratio | 2.76 | |
| PB Ratio | 1.47 | |
| EV/EBITDA | 9.07 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $16.72B | |
| Cash & Equivalents | $2.38B | |
| Total Assets | $28.05B | |
| Current Assets | $7.46B | |
| Total Liabilities | $11.33B | |
| Current Liabilities | $5.53B | |
| Total Debt | $6.72B | |
| Short Term Debt | $1.84B | |
| Accounts Payable | $424.20M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $7.46B | |
| Operating Expenses | $5.15B | |
| Cost Of Goods Sold | $2.31B | |
| SG&A | $2.40B | |
| D&A | $673.20M | |
| Interest Expense | $0.00 | |
| Income Tax | $273.80M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $2.88B | |
| CFI | -$799.20M | |
| CFF | -$683.50M | |
| Capex | $359.80M | |
| Free Cash Flow | $2.52B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| Wells Fargo | → | |
| HSBC | → | |
| Piper Sandler | → | |
| Stifel | → | |
| Bernstein | → | |
| RBC Capital | → | |
| Morgan Stanley | → | |
| Jefferies | ||
| Needham | → |
Analyst sentiment
Institutional ownership
Screeners with BIIB
Data Sources & References
- BIIB Official Website www.biogen.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/875045/000087504525000049/0000875045-25-000049-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/875045/000087504525000009/0000875045-25-000009-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- BIIB Profile on Yahoo Finance finance.yahoo.com/quote/BIIB
- BIIB Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/biib
FAQ
What is the ticker symbol for Biogen Inc.?
The ticker symbol for Biogen Inc. is NASDAQ:BIIB
Does Biogen Inc. pay dividends?
No, Biogen Inc. does not pay dividends
What sector is Biogen Inc. in?
Biogen Inc. is in the Healthcare sector
What industry is Biogen Inc. in?
Biogen Inc. is in the General Drug Manufacturers industry
What country is Biogen Inc. based in?
Biogen Inc. is headquartered in United States
When did Biogen Inc. go public?
Biogen Inc. initial public offering (IPO) was on September 17, 1991
Is Biogen Inc. in the S&P 500?
Yes, Biogen Inc. is included in the S&P 500 index
Is Biogen Inc. in the NASDAQ 100?
No, Biogen Inc. is not included in the NASDAQ 100 index
Is Biogen Inc. in the Dow Jones?
No, Biogen Inc. is not included in the Dow Jones index
When was Biogen Inc. last earnings report?
Biogen Inc.'s most recent earnings report was on October 30, 2025
When does Biogen Inc. report earnings?
The next expected earnings date for Biogen Inc. is February 11, 2026